GLPwatch
Papers (10386)
Page 131 of 174, ranked by citation count.
- Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.
- Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver.
- Inclusion of drugs on the World Health Organization's Essential Medicines List: A game-changer for obesity?
- Incretin-based approaches for type 2 diabetes therapy: effects on circulating cytokines and adipocyte's secretome.
- Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.
- Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists.
- Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes.
- A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.
- Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice.
- Drug updates and approvals: 2015 in review.
- Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.
- GLP1R agonists: primary cardiovascular prevention and oral administration.
- Clinical studies on anti-obesity medications in Arab countries.
- Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.
- Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes.
- Evaluating the Efficacy of ChatGPT vs. Google Gemini in Generating Patient Education Materials for GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Tirzepatide): A Cross-Sectional Study.
- Pre-immunization of diet-induced obese male mice with inactivated pathogens increases power in a liraglutide intervention study.
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.
- Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.
- Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.
- Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.
- Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss.
- Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
- The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
- From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.
- A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.
- Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
- Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
- The role of mast cells in cellular modifications evoked by Exendin-4 in treated wounds: a preclinical study.
- [Effect of adipose-derived mesenchymal stem cells and liraglutide on acute lung injury].
- [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
- At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
- Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
- Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.
- Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide.
- Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes.
- Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
- A LEADER in the management of type 2 diabetes and cardiorenal disease.
- Synthetic protease-activated class B GPCRs.
- [Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity].
- Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
- Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
- Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
- Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
- Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy.
- To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.
- Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.
- Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening.
- Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.
- Dulaglutide and pregnancy: a comprehensive safety assessment using the <i>ex vivo</i> placenta perfusion and <i>in vitro</i> models.
- Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.
- Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
- Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
- Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.
- Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.
- Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
- Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.